Business Wire

Leading DACH-Based Global Röchling Group Selects Everbridge Critical Event Management (CEM) SaaS Platform for Employee Safety and Business/IT Resilience

Share

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced that the Röchling Group, a global leading plastics manufacturer, will adopt the Everbridge CEM solution to help protect Röchling’s workforce and business operations against critical events of all kinds, including the ongoing COVID-19 pandemic. Everbridge CEM provides Röchling with a unified, common operating platform for managing organizational risk and accelerating communications, response, and recovery efforts to mitigate impact to employees or disruptions to business and IT operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005455/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

DACH-Based Global Röchling Group Selects Everbridge Critical Event Management (CEM) (Photo: Business Wire)

Headquartered in Mannheim, Germany, Röchling’s global workforce includes 11,500 employees in 90 locations and 25 countries. Röchling’s three divisions Industrial, Automotive and Medical generated joint annual sales of 2.352 billion euros in 2019. The nearly 200-year-old company has transformed the lives of people for almost a century with its customized plastics: reducing the weight of cars, making medication packaging more secure, and improving industrial applications.

“The Röchling Group is committed to the safety of our global workforce and to ensuring the protection of our business assets and IT operations,” said Klaus-Peter Fett, Chief Information and Digital Officer at Röchling. “Everbridge CEM represents a unique solution in its ability to help us digitally transform Röchling’s corporate health, risk and security programs, providing one unified platform to manage all potential risks. In today’s environment, Everbridge provides us a proactive approach to risk management, employee safety and business continuity.”

To support the company’s goal of ensuring safety and productivity for local, remote and traveling employees, as well as organizational resiliency and business continuity, Röchling desired a solution that would enable the enterprise security team to better visualize, anticipate and manage risk events, disruptions and IT interruptions. Everbridge CEM enables Röchling to merge and display robust data sources regarding organizational assets (employees, travelers, buildings) and risk events (global pandemic, terrorism, natural disasters, weather, health risks) into a highly visual common operating view. This will enable Röchling to digitally transform how the company assesses threats, drives a coordinated response, and avoids costs and impacts to life safety, while enabling the business to operate and grow despite risk.

“With critical events such as COVID-19 on the rise, we are proud to support Röchling with their return to office efforts, in addition to improving mean time to respond to IT and business disruptions,” said Javier Colado, Senior Vice President, International at Everbridge. “We are committed to delivering a secure, reliable and innovative Critical Event Management platform that enables enterprise security and resiliency leaders to deliver value and safety to their global teams.”

Over 5,400 businesses, governments, and healthcare organizations currently rely on Everbridge’s CEM Platform to assess threats, monitor the wellbeing of their workforces, rapidly communicate warnings, protect business assets, and accelerate the analysis of their operational response.

“As a global leading plastics manufacturer, the Röchling Group represents a significant milestone in the continued adoption of our CEM platform in the DACH region,” said Andreas Junck, GM of Everbridge DACH Region. “I look forward to working with Röchling, a global player and industry champion with nearly 200 years of history and success in Germany and all over the world.”

As the global leader in critical event management and public warning, Everbridge and its platform reach over 650 million people across the world while serving leading Fortune 500 companies as well as cities, states, and entire countries.

About Röchling

The Röchling Group has been shaping industry. Worldwide. For nearly 200 years. We transform the lives of people every day with our customized plastics: they reduce the weight of cars, make medication packaging more secure and improve industrial applications. Our workforce of around 11,500 people is located in the places where our customers are – in 90 locations in 25 countries. The Group’s three divisions generated joint annual sales of 2.352 billion euros in 2019.

The Industrial division is the expert for optimal materials for every use. We develop and supply individual products made of plastic for all industrial areas. This is why we have the broadest product range of thermoplastics and composite materials. We supply our customers with semi-finished products or machined components.

The Automotive division advances mobility. Our product solutions in the areas of aerodynamics, propulsion and structural lightweight help solve major challenges. We protect the environment while also improving the driving experience.

The Medical division is the reliable partner to leading global companies when it comes to the components, services and smart plastic products that are needed in the healthcare industry. We develop solutions in the fields of diagnostics, fluid management, pharma as well as surgery and interventional.

For more information visit www.roechling.com

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,400 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 20 cities around the globe. For more information visit www.everbridge.com

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Everbridge Contacts:
Jeff Young
Media Relations
jeff.young@everbridge.com
781-859-4116

Joshua Young
Investor Relations
joshua.young@everbridge.com
781-236-3695

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release

Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release

Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release

Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye